Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Development of the Oral Microbiota01:28

Development of the Oral Microbiota

The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...
Microbiota Modulation by Antibiotics01:21

Microbiota Modulation by Antibiotics

Antibiotics have revolutionized modern medicine by saving countless lives from bacterial infections. However, their widespread use has inadvertently harmed the delicate balance of the human gut microbiota. The gut microbiota, a complex community of bacteria, archaea, viruses, and fungi, plays a vital role in regulating metabolism, immune responses, and maintaining intestinal health. Antibiotics, especially broad-spectrum types, disrupt this ecosystem by eradicating both harmful and beneficial...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Development of Human Microbiota01:30

Development of Human Microbiota

The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from the skin...
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Antibiotic Selection00:57

Antibiotic Selection

Overview

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exposure to 26.5 GHz, 5G modulated and unmodulated signal, does not affect key cellular endpoints of human neuroblastoma cells.

Scientific reports·2025
Same author

Delayed episode of necrotising enterocolitis in an ex-preterm infant after intravitreal administration of low-dose ranibizumab for the treatment of retinopathy of prematurity.

BMJ case reports·2024
Same author

Visceral Leishmaniasis in Immunocompetent Hosts in Brescia: A Case Series and Analysis of Cytokine Cascade.

Microorganisms·2024
Same author

Neutropenia in Preterm Infants.

Current pediatric reviews·2022
Same author

Sensory Stimulation in the NICU Environment: Devices, Systems, and Procedures to Protect and Stimulate Premature Babies.

Children (Basel, Switzerland)·2021
Same author

Neonatal Respiratory Distress and Airway Emergency: Report of Two Cases.

Children (Basel, Switzerland)·2021

Related Experiment Video

Updated: Jun 20, 2026

Probiotic Studies in Neonatal Mice Using Gavage
10:36

Probiotic Studies in Neonatal Mice Using Gavage

Published on: January 27, 2019

Antibiotics for the newborn.

Gaetano Chirico1, Fabiana Barbieri, Claudia Chirico

  • 1Department of Neonatology and Neonatal Intensive Care, Spedali Civili, Brescia, Italy. gaechirico@alice.it

The Journal of Maternal-Fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
|September 1, 2009
PubMed
Summary

Antibiotic use in newborns requires careful consideration of their unique physiology and organ immaturity. Dosing and duration must be adjusted based on pharmacokinetic data for optimal safety and efficacy in neonates.

More Related Videos

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis
08:46

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

Published on: August 12, 2020

Effect of Hyaluronic Acid 35 kDa on an In Vitro Model of Preterm Small Intestinal Injury and Healing Using Enteroid-Derived Monolayers
09:36

Effect of Hyaluronic Acid 35 kDa on an In Vitro Model of Preterm Small Intestinal Injury and Healing Using Enteroid-Derived Monolayers

Published on: July 28, 2022

Related Experiment Videos

Last Updated: Jun 20, 2026

Probiotic Studies in Neonatal Mice Using Gavage
10:36

Probiotic Studies in Neonatal Mice Using Gavage

Published on: January 27, 2019

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis
08:46

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

Published on: August 12, 2020

Effect of Hyaluronic Acid 35 kDa on an In Vitro Model of Preterm Small Intestinal Injury and Healing Using Enteroid-Derived Monolayers
09:36

Effect of Hyaluronic Acid 35 kDa on an In Vitro Model of Preterm Small Intestinal Injury and Healing Using Enteroid-Derived Monolayers

Published on: July 28, 2022

Area of Science:

  • Neonatal pharmacology
  • Pediatric infectious diseases
  • Clinical pharmacy

Background:

  • Neonates have high susceptibility to infections, making antibiotics a common treatment.
  • Neonatal physiology, including immature kidney and liver function, significantly impacts antibiotic efficacy and safety.
  • Factors like gestational age, birth weight, and intrauterine growth restriction influence drug pharmacokinetics in newborns.

Purpose of the Study:

  • To review the key considerations for antibiotic therapy in neonates.
  • To highlight the importance of pharmacokinetic and pharmacodynamic parameters in neonatal antibiotic dosing.
  • To discuss current recommendations for antibiotic use and emerging applications in neonatal care.

Main Methods:

  • Review of existing literature on neonatal antibiotic pharmacokinetics and pharmacodynamics.
  • Analysis of current clinical practices and guidelines for antibiotic use in newborns.
  • Examination of recent studies on novel applications of antibiotics in neonatal medicine.

Main Results:

  • Antibiotic dosing, timing, and administration routes must account for neonatal variability in absorption, distribution, metabolism, and excretion.
  • Ampicillin and gentamicin remain a standard initial empiric therapy for suspected neonatal sepsis.
  • Other antibiotics like cephalosporins, carbapenems, and glycopeptides require judicious use to maximize efficacy and minimize toxicity.
  • Macrolides, such as erythromycin and azithromycin, show promise for non-antibacterial indications like gastrointestinal dysmotility and prevention of bronchopulmonary dysplasia.

Conclusions:

  • Optimizing antibiotic therapy in neonates necessitates a personalized approach based on individual physiological characteristics and pharmacokinetic data.
  • Careful selection and judicious use of antibiotics are crucial for managing infections and preventing adverse outcomes in newborns.
  • Emerging evidence suggests potential benefits of macrolides beyond their antibacterial properties in specific neonatal conditions.